Regulation of AT1R-signaling and pathology in vessels through microRNA
通过 microRNA 调节血管中 AT1R 信号传导和病理学
基本信息
- 批准号:8657108
- 负责人:
- 金额:$ 38.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-07-01 至 2016-04-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingAngiotensin IIAngiotensin II ReceptorAngiotensin II Type 1 Receptor BlockersAngiotensin ReceptorAngiotensinogenAngiotensinsAntihypertensive AgentsAortaAortic AneurysmAtherosclerosisBindingBiochemicalBiogenesisBiologyBlood PressureBlood VesselsBrainCardiacCardiac MyocytesCardiovascular DiseasesCardiovascular PhysiologyCardiovascular systemCell LineCell SurvivalCell modelCellsCholesterolChronicChronic DiseaseChymosinDataDilated CardiomyopathyDiseaseDisease ProgressionDown-RegulationDrug TargetingEpithelial CellsExperimental ModelsFibrosisFunctional RNAFunctional disorderGene ExpressionGene Expression RegulationGene TargetingGenetic TranscriptionGoalsHealthHeartHeart HypertrophyHeart failureHomeostasisHormonesHumanHypertrophyInfusion proceduresInterventionKidneyKnock-in MouseKnowledgeLinkMammary NeoplasmsMediatingMediator of activation proteinMessenger RNAMicroRNAsMitogen-Activated Protein KinasesModelingMolecularMolecular AnalysisMolecular ProfilingMusMuscle CellsOrganPathologyPathway interactionsPatternPeptidyl-Dipeptidase APhysiologicalPreventionProcessProtein Tyrosine KinaseProteinsPublic HealthReceptor ActivationReceptor CellReceptor SignalingReceptor, Angiotensin, Type 1RegulationRegulator GenesRenin-Angiotensin SystemResearchRoleSignal TransductionSmooth Muscle MyocytesStagingStimulusStudy modelsSystemTestingTherapeuticTissuesTranscriptTransgenic MiceTumor AngiogenesisType 2 Angiotensin II ReceptorUp-RegulationWater-Electrolyte Balancebasecell growthgain of functionheart cellhemodynamicsimprovedin vivokidney cellkidney vascular structureknowledge basemutantnovelnucleotide analogprogramsreceptorreceptor couplingresponsetumor growth
项目摘要
DESCRIPTION (provided by applicant): The long-term goal of our research program is to elucidate microRNA mechanisms that alter normal regulation of genes in response to overactivity of the angiotensin II type 1 receptor (AT1R). Angiotensin II (AngII) is the classical mediator of the effects of the renin-angiotensin system on the cardiovascular homeostasis. This receptor regulates gene expression targeted by the AT1R-blockers (ARB), a widely used class of anti- hypertensive drugs that are currently in trial for the prevention of vascular, renal and cardiac hypertrophy, aortic aneurism, vascular fibrosis, breast tumor growth and angiogenesis. Inhibition of AT1R in renal, vascular and cardiac cells by ARBs is protective, but the activation o the receptor causes hypertrophy and progressive fibrosis of the respective organs/tissues. In preliminary studies we have discovered that chronic activation of AT1R deregulates gene expression through both transcriptional and post-transcriptional mechanisms. To directly link deregulation of gene expression to hypertrophy and fibrosis, we profiled mRNA and microRNA (miRNA) expression in the AT1R TG mice aorta, heart, and in HL1-AT1R (cardiomyocyte) and the VSMC-AT1R cell lines. Typical transcriptional and miRNA regulatory mechanisms are significantly altered in all of the experimental models. In a separate study, we have shown significantly altered miRNA expression profile in dilated cardiomyopathy human hearts. The altered miRNAs target gene networks that do account for compensatory remodeling in human heart failure. These novel studies suggest that mRNA and miRNA profiles, together, contribute to AT1R biology in health and disease. Our current proposal will focus on the novel roles of two AT1R-modulated microRNAs: miR-205 and mir-483. Three Specific Aims are proposed to test the hypothesis that specific transcriptional and post-transcriptional regulatory mechanisms tilt the dynamics of typical hypertrophy and fibrosis signaling towards a disease connotation. They are: (i) to determine miR-205 mechanisms which alter critical signaling components in models of hypertrophy and fibrosis, (ii) to determine the miR-483 mechanism of up-regulation of the rennin angiotensin system, and (iii) to determine the AT1R regulated mechanisms of biogenesis and the stability of miR-205 and miR-483. If the AT1R activity is not regulated properly, AngII stimulus becomes chronic and can damage the tissue, as well as contribute to chronic disorders of blood vessels, kidney and heart. A clear understanding of these mechanisms is important to improve the therapeutic application of ARBs. These proposed studies will advance our knowledge of the biology of AT1R signaling causing hypertrophy and fibrosis. There is potential relevance for this knowledge base in understanding normal functioning aorta, vasculature in brain, kidney and heart, as well as the pathology of heart failure, atherosclerosis and aortic aneurysm.
描述(申请人提供):我们研究计划的长期目标是阐明在血管紧张素II 1型受体(AT1R)过度活动时改变基因正常调节的microRNA机制。血管紧张素II(AngII)是肾素-血管紧张素系统影响心血管内稳态的经典介质。该受体调节AT1R受体阻滞剂(ARB)靶向的基因表达,ARB是一类广泛使用的抗高血压药物,目前正在试验中,用于预防血管、肾脏和心脏肥大、主动脉瘤、血管纤维化、乳腺肿瘤生长和血管生成。ARB对肾、血管和心肌细胞AT1R的抑制是保护性的,但受体的激活会导致相应器官/组织的肥大和进行性纤维化。在初步研究中,我们发现AT1R的慢性激活通过转录和转录后机制来解除对基因表达的调控。为了直接将基因表达的失控与肥大和纤维化联系起来,我们对AT1R TG小鼠的主动脉、心脏以及HL1-AT1R(心肌细胞)和VSMC-AT1R细胞系中的mRNA和microRNA(MiRNA)的表达进行了分析。在所有的实验模型中,典型的转录和miRNA调节机制都发生了显著的变化。在另一项单独的研究中,我们发现扩张型心肌病患者的miRNA表达谱发生了显著变化。改变的miRNAs针对的是基因网络,这些基因网络确实解释了人类心力衰竭的代偿性重构。这些新的研究表明,mRNA和miRNA图谱共同有助于AT1R在健康和疾病中的生物学。我们目前的建议将集中在两个AT1R调节的microRNAs:miR-205和mir-483的新角色上。提出了三个具体的目标来检验这一假说,即特定的转录和转录后调控机制使典型的肥大和纤维化信号的动力学向疾病内涵倾斜。它们是:(I)确定改变肥大和纤维化模型中关键信号成分的miR-205机制,(Ii)确定上调肾素血管紧张素系统的miR-483机制,以及(Iii)确定AT1R调节生物发生的机制以及miR-205和miR-483的稳定性。如果AT1R活性调节不当,血管紧张素转换酶刺激就会变成慢性刺激,并可能损害组织,并导致血管、肾脏和心脏的慢性疾病。对这些机制的清楚理解对于提高ARBS的治疗应用具有重要意义。这些拟议的研究将促进我们对AT1R信号导致肥大和纤维化的生物学知识的了解。这一知识库在了解正常功能的主动脉、脑、肾和心脏的血管系统以及心力衰竭、动脉粥样硬化和主动脉瘤的病理方面具有潜在的相关性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sadashiva S Karnik其他文献
イルベサルタンのAT1受容体非依存性効果-ロサルタンとの比較
厄贝沙坦的 AT1 受体依赖性作用 - 与氯沙坦的比较
- DOI:
- 发表时间:
2010 - 期刊:
- 影响因子:0
- 作者:
木谷嘉博;三浦伸一郎;藤野正礼;Sadashiva S Karnik;朔啓二郎 - 通讯作者:
朔啓二郎
Sadashiva S Karnik的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sadashiva S Karnik', 18)}}的其他基金
Structure-Guided Analysis of Mechanisms of AT1R Functions
AT1R 功能机制的结构引导分析
- 批准号:
9336426 - 财政年份:2016
- 资助金额:
$ 38.47万 - 项目类别:
Regulation of AT1R-signaling and pathology in vessels through microRNA
通过 microRNA 调节血管中 AT1R 信号传导和病理学
- 批准号:
8398599 - 财政年份:2012
- 资助金额:
$ 38.47万 - 项目类别:
Regulation of AT1R-signaling and pathology in vessels through microRNA
通过 microRNA 调节血管中 AT1R 信号传导和病理学
- 批准号:
8485661 - 财政年份:2012
- 资助金额:
$ 38.47万 - 项目类别:
Phosphoproteome and Ang II-induced VSMC Gene Expression
磷酸化蛋白质组和 Ang II 诱导的 VSMC 基因表达
- 批准号:
7025391 - 财政年份:2006
- 资助金额:
$ 38.47万 - 项目类别:
Phosphoproteome and Ang II-induced VSMC Gene Expression
磷酸化蛋白质组和 Ang II 诱导的 VSMC 基因表达
- 批准号:
7171551 - 财政年份:2006
- 资助金额:
$ 38.47万 - 项目类别:
Phosphoproteome and Ang II-induced VSMC Gene Expression
磷酸化蛋白质组和 Ang II 诱导的 VSMC 基因表达
- 批准号:
7780029 - 财政年份:2006
- 资助金额:
$ 38.47万 - 项目类别:
相似海外基金
Early endothelial function activation by angiotensin II receptor blockers prevents vascular damage in a model of diabetes
血管紧张素 II 受体阻滞剂早期激活内皮功能可预防糖尿病模型中的血管损伤
- 批准号:
493141 - 财政年份:2023
- 资助金额:
$ 38.47万 - 项目类别:
Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta
血管紧张素II受体阻滞剂对主动脉缩窄修复患者心血管重塑的临床疗效及作用机制
- 批准号:
10734120 - 财政年份:2023
- 资助金额:
$ 38.47万 - 项目类别:
Targeting cancer-associated fibroblasts and tumour hypoxia with angiotensin II receptor blockers
使用血管紧张素 II 受体阻滞剂靶向癌症相关成纤维细胞和肿瘤缺氧
- 批准号:
445961 - 财政年份:2021
- 资助金额:
$ 38.47万 - 项目类别:
Operating Grants
Antitumor effect of HCC and exosome microRNA by angiotensin II receptor blockers and molecular target drugs
血管紧张素II受体阻滞剂和分子靶向药物对HCC和外泌体microRNA的抗肿瘤作用
- 批准号:
19K17401 - 财政年份:2019
- 资助金额:
$ 38.47万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects
血管紧张素 II 受体阻滞剂对内皮功能的多效性激活对其保护性抗血管重塑作用至关重要
- 批准号:
411570 - 财政年份:2019
- 资助金额:
$ 38.47万 - 项目类别:
Heterogeneity of Angiotensin II Receptor Blockers in the inhibition of Marfan-associated Aortic Root Dilation Independent of Blood Pressure Effects
血管紧张素 II 受体阻滞剂抑制马凡相关主动脉根部扩张的异质性,与血压影响无关
- 批准号:
391615 - 财政年份:2018
- 资助金额:
$ 38.47万 - 项目类别:
Relationship between serum EETs concentrations and cardiovascular events in patients taking angiotensin II receptor blockers
服用血管紧张素II受体阻滞剂的患者血清EETs浓度与心血管事件的关系
- 批准号:
26460229 - 财政年份:2014
- 资助金额:
$ 38.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The development of new angiotensin II receptor vaccine
新型血管紧张素II受体疫苗的研制
- 批准号:
25870715 - 财政年份:2013
- 资助金额:
$ 38.47万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
- 批准号:
8531707 - 财政年份:2012
- 资助金额:
$ 38.47万 - 项目类别:
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
- 批准号:
8397394 - 财政年份:2012
- 资助金额:
$ 38.47万 - 项目类别:














{{item.name}}会员




